New weight-loss shot appears to outperform other obesity drugs on market

Eli Lilly announced that its new weight-loss drug retatrutide significantly outperforms existing obesity medications, with trial participants losing an average of 28.3% of body weight over 80 weeks. The once-weekly injection led to 45.3% of participants achieving at least 30% weight loss, representing a major advancement in obesity treatment.